BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

New Cancer Drug Creates Buzz for Roche (RHHBY), Hunts for Bolt-on M&As: CEO


10/16/2012 8:44:33 AM

A new cancer drug being trialed by Swiss Drugmaker Roche Holding will present a key opportunity for the company in the coming months, Roche CEO Severin Schwan told CNBC Tuesday. “It’s a very big opportunity. Perjeta is a new novel medicine which is combined with Herceptin and clinical data is very exciting. We’ll present more data at an upcoming conference but we’ve seen good uptake in the United States where it has just been released,” Schwan said. He admitted that price pressure was less of a factor for Roche than for other pharmaceutical companies within Europe. On average it stands at around 5 percent on sales but for Roche was just 2 percent. “It’s at a much lesser extent for us in Europe so the innovation of our medicine and the clinical benefit we provide to our patients protects us somewhat on that front,” he added. The Swiss drugmaker confirmed its full year outlook Tuesday after strong sales of cancer drugs in the third quarter and a weaker Swiss franc against the dollar and Japanese yen.



Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->